Journal of Adolescent Health 37 (2005) 517.e1 517.e5. Original article. Manuscript received May 3, 2005; manuscript accepted August 10, 2005
|
|
- Lorena Harrington
- 5 years ago
- Views:
Transcription
1 Journal of Adolescent Health 37 (2005) 517.e1 517.e5 Original article Immunogenicity and reactogenicity of a reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine in healthy Taiwanese children and adolescents Li-Min Huang, MD, PhD a, Luan-Yin Chang, MD, PhD a, Haiwen Tang, MD, PhD b, Hans L. Bock, MD b, Chun-Yi Lu, MD a, Fu-Yuan Huang, MD c, Tzou-Yien Lin, MD d, *, and Chin-Yun Lee, MD a a Department of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan b GlaxoSmithKline Biologicals, Rixensart, Belgium c Department of Pediatrics, Mackay Memorial Hospital, Taipei, Taiwan d Chang Gung Children s Hospital and Chang Gung University, College of Medicine, Taoyuan, Taiwan Manuscript received May 3, 2005; manuscript accepted August 10, 2005 Abstract Keywords: Purpose: Disease caused by Bordetella pertussis is increasingly being identified among older children and adults in immunized populations, indicating a waning of the vaccine-induced immunity. These findings suggest the need for booster immunization of older children and adults. Modern acellular reduced-antigen-content vaccines have been developed, which can be given as a booster in individuals more than 4 years of age. This study was to assess the immunogenicity and reactogenicity of Boostrix TM, GlaxoSmithKline Biologicals reduced-antigen-content diphtheria-tetanus acellular pertussis (dtpa) vaccine, when administered as a booster in healthy subjects previously primed with DTP vaccine. Methods: Healthy Taiwanese children and adolescents aged 6 8 years and years, previously primed with DTP vaccine, were enrolled. All received one dose of Boostrix TM. Two blood samples were taken from each of them, one before vaccination and one at 1 month after vaccination. Serum antibodies to diphtheria and tetanus toxoids and immunoglobulin G (IgG) antibodies against the pertussis components PT, FHA and PRN were measured by enzyme-linked immunosorbent assay (ELISA) technique. Adverse reactions following vaccination were recorded. Results: A total of 180 subjects were recruited. The vaccine response rates to the pertussis antigens ranged between %. There were no serious adverse events reported during the study period. Conclusions: The results of this study suggest that Boostrix TM may be safely and effectively administered as a booster dose to children previously primed with DTP vaccine Society for Adolescent Medicine. All rights reserved. Reduced-antigen-content dtpa vaccine; Bordetella pertussis; Taiwan; Booster vaccination; Adolescents Universal infant immunization against diphtheria, tetanus, and pertussis is one of the major goals of the World Health Organization (WHO) Expanded Program on Immunization (EPI). Diphtheria-tetanus-pertussis (DTP) primary vaccination *Address correspondence to: Dr. Tzou-Yien Lin, Chang Gung Children s Hospital, No. 5, Fu-shin St, Kweishang, Taipei, Taiwan. address: pidlin@adm.cgmn.org.tw of infants followed by a booster dose in the second year of life is almost a universal practice [1]. In the prevaccination era, pertussis infection commonly occurred in early life. The subsequent natural immunity was then maintained by periodic exposure to the organism (Bordetella pertussis), which acted as a natural booster [2]. Childhood immunization against pertussis has been effective in decreasing the incidence of pertussis but has not eliminated the circulation of Bor X/05/$ see front matter 2005 Society for Adolescent Medicine. All rights reserved. doi: /j.jadohealth
2 517.e2 L.-M. Huang et al. / Journal of Adolescent Health 37 (2005) 517.e1 517.e5 detella pertussis [3]. Although the incidence of pertussis in young children has been markedly reduced since the successful implementation of infant immunization programs, there has been a subsequent increase in the incidence in older children, adolescents and adults in immunized populations [3 10]. Neither vaccination-acquired nor natural immunity from pertussis is life long. An increasing number of adults and adolescents with waning immunity, especially in wellvaccinated populations where natural boosting has been reduced, are now susceptible to pertussis reinfection [8,11 14]. The major cause for concern is the potential for older infected family members to serve as reservoir of infection to young infants, which has been shown in several household studies [11,12,14 18]. Furthermore, because the symptoms are generally atypical in adults [19], adult infection is often difficult to diagnose [20] and this situation creates the potential for further spread. Treatment with antibiotics is effective in clearing the organism and limiting spread of the disease only within the first three weeks after onset of symptoms [21]. These findings suggest the need for booster immunizations of older children and adults, with the goal of preventing transmission of B. pertussis from these age groups to infants. Pertussis vaccine boosters have not previously been recommended after seven years of age, mainly due to the high reactogenicity of traditional whole-cell pertussis vaccines [22] in older children and the belief that pertussis is both uncommon and mild in older children, adolescents and adults. Although combined diphtheria-tetanus-pertussis (DTPa) vaccines, which are less reactogenic than whole-cell vaccines [23,24], have become routine pediatric vaccines in many countries, their reactogenicity increases with successive doses, making the pediatric formulation less suitable for older individuals [25]. The recent development of a reduced-antigen-content diphtheria-tetanus acellular pertussis vaccine (dtpa) provides health practitioners with a new option. In many countries, immunity to diphtheria and tetanus is currently maintained by booster vaccination at 5- to 10-year intervals. A reduced-antigen-content diphtheria-tetanus (Td) vaccine is used to improve tolerability while eliciting an adequate immune response. Utilizing a reduced antigen dtpa vaccine would provide the added benefit of boosting waning pertussis antibodies in addition to maintaining immunity to diphtheria and tetanus. This article reports the immunogenicity and reactogenicity of Boostrix, GlaxoSmithKline Biologicals reduced-antigen-content diphtheria-tetanus-acellular pertussis (dtpa) vaccine, when administered as a booster vaccination to healthy Taiwanese children six to eight years of age and adolescents and young adults aged 15 to 20 years, all of whom were previously primed with DTP vaccine. Materials and Methods Subjects and ethics Sixty healthy children six to eight years of age and 120 healthy young adolescents and adults 15 to 20 years of age who were previously primed with four doses of DTP vaccine according to local schedule, were enrolled. This study was conducted at the National Taiwan University Hospital and Chang Gung Children s Hospital in Taiwan. The conduct of this study followed the Declaration of Helsinki and Good Clinical Practice guidelines, with approval of the respective ethical review committee and with witnessed written parental informed consent before the start of the study. Children and adolescents/young adults were excluded from the study if they had a history of allergic reaction to any of the vaccine components, had a history of diphtheria or tetanus disease or a history of confirmed pertussis disease within the previous five years, had any chronic or neurological illness, or had received any blood products. Vaccine Reduced-antigen-content diphtheria-tetanus-acellular pertussis (dtpa) vaccine, Boostrix (GlaxoSmithKline Biologicals, Rixensart, Belgium), was used in this study. One dose (0.5 ml) contained diphtheria toxoid ( 2 International Units, IU), tetanus toxoid ( 20 IU), Pertussis toxin (PT; 8 g), filamentous haemagglutinin (FHA; 8 g), and pertactin (PRN; 2.5 g). The same manufacturer s lot of the dtpa vaccine was used in both studies. Study design An open label design was used. All subjects received a single booster dose of dtpa vaccine intramuscularly in the deltoid region. Data collection Diary cards provided by the investigator were used by parents/guardians to record solicited local reactions at the injection site (pain, redness and swelling) and systemic (general) symptoms (axillary temperature, headache, fatigue and gastrointestinal symptoms) on the day of vaccination and for the 14 subsequent days (15-day follow-up period). Symptoms were graded from 1 to 3 in intensity with total (any symptom irrespective of intensity and relationship to vaccination) and Grade 3 (symptoms that prevented normal activities) incidence being reported here. Grade 3 pain was defined as spontaneously painful. For local swelling and redness, the largest diameter was measured and a diameter of 50 mm was defined as intensity Grade 3. Fever was defined as axillary temperature 37.5 C, and intensity
3 L.-M. Huang et al. / Journal of Adolescent Health 37 (2005) 517.e1 517.e5 517.e3 Grade 3 as a temperature 39.0 C. Unsolicited symptoms reported during the 30-day follow-up period after the vaccine dose and serious adverse events (SAEs) reported during the entire study period were also recorded. Immunological assays Blood samples were collected before the vaccine dose (pre) and one month after the vaccine dose (post). Serum antibodies to diphtheria and tetanus toxoids and immunoglobulin G (IgG) antibodies against the pertussis components PT, FHA and PRN were measured by enzyme-linked immunosorbent assay (ELISA) technique. For anti-diphtheria and anti-tetanus antibodies, titres above the assay cut-offs were considered to be seroprotective. For pertussis antigens, subjects with antibody titres above the assay cut-off were termed as seropositive. Furthermore, because there is no defined serological correlate of protection for B. pertussis, a vaccine response was defined as post-vaccination antibody titres above the assay cut-off value in initially seronegative subjects, and as at least a twofold increase in antibody titres from prevaccination to postvaccination in initially seropositive subjects. Statistical analysis All analyses performed to assess the antibody response and reactogenicity of a single dose of GSK Biologicals dtpa vaccine were descriptive. At each blood sampling time point (pre- and postbooster), seroprotection rates against diphtheria and tetanus toxoids, vaccine response rates to pertussis antigens, and geometric mean concentrations (GMCs) with 95% confidence intervals (CI) were tabulated for all antibodies. The incidences of local and general adverse events (solicited/unsolicited after the vaccine dose) were calculated with exact 95% CI, in addition to tabulating intensity and relationship. Serious adverse events and discontinuation due to adverse events were described. Results Demographics The mean age of the enrolled children was six years, with a standard deviation of.13 years in the group of six- to eight-year-olds. All 60 children completed the study. All were Asian and the male-to-female ratio was approximately 1:1. All 60 were included in the reactogenicity analysis and 59 were included in the immunogenicity analysis (one subject was outside of the accepted age range). The mean age in the group of 15- to 20-year-olds was 17 years (SD 1.64 years). All subjects were Asian and the male-to-female ratio was approximately.5: 1. Of the 120 subjects enrolled, 119 were vaccinated and included in the analyses. One subject did not return for the postvaccination blood sampling. Immunogenicity One month after the vaccine dose, all subjects in both age groups had seroprotective anti-diphtheria and anti-tetanus antibody titres and a vaccine response against the pertussis antigens was elicited in most subjects ( %) (Table 1). GMCs increased significantly from prebooster to postbooster vaccination in both groups (data not shown). In the group of six- to eight-year-olds, there was a 22-fold increase for anti-diphtheria and a 52-fold for anti-tetanus concentrations. Anti-PT and anti-fha concentrations increased 24-fold and anti-prn increased 25-fold. In the group of 15- to 20-year-olds, GMC of anti-diphtheria increased 19-fold, anti-tetanus increased 23-fold, anti-pt increased 10-fold, anti-fha 32-fold, and anti-prn 34-fold. Reactogenicity In both groups, local reactions were reported more frequently than were general symptoms (approximately three times more often in the six- to eight-year-olds and twice as Table 1 Immunogenicity results following reduced-antigen dtpa vaccine administered to children and adolescents Vaccine antigen Subjects n Age (years) Response 95% CI GMC 95% CI (%) a Diphtheria Tetanus PT FHA PRN a Vaccine response definition: diphtheria and tetanus: post-vaccination antibody titer 0.1IU/mL by ELISA; pertussis antibodies: initially seronegative participants before vaccination with postvaccination antibody titer 5 EL.U/mL; initially seropositive participants with post-vaccination antibody titer at least twofold higher than prevaccination titer.
4 517.e4 L.-M. Huang et al. / Journal of Adolescent Health 37 (2005) 517.e1 517.e5 Table 2 Reactogenicity: incidence of solicited local and general symptoms reported within the 15-day follow-up period after vaccination Adverse event often in the 15- to 20-year-olds). For both groups, pain at injection site and fatigue were the most frequently reported solicited local and general symptoms, respectively (Table 2). No Grade 3-solicited local or general symptoms were reported by the six- to eight-year-old group; two cases were reported in the older age group, both of which resolved by Day 18 postvaccination without sequelae. No cases of fever were reported by the younger children. The six cases reported in the 15- to 20-year-olds were assessed by the investigator as being unrelated to vaccination. The majority of the solicited local and general symptoms had an onset within 48 hours after vaccination. No unsolicited symptoms were reported in the younger age group. Seven of the 15- to 20-year-olds reported an unsolicited symptom within 30 days after vaccination and were assessed as having a probable or suspected relationship to vaccination. These included injection site reaction, pain, diarrhea, upper respiratory tract infection, pharyngitis, rhinitis and lymphadenopathy. No serious adverse events were reported and no child or adolescent/young adult experienced an adverse event that led to discontinuation from the study. Discussion 6 to 8-year-olds (n 60) 15 to 20-year-olds (n 119) % 95% CI % 95% CI Local injection site reactions Pain Total Grade Redness Total Swelling Total Grade General symptoms 6 to 8 year olds 15 to 20 year olds Fever Total Fatigue Total Gastrointestinal Total Headache Total n Overall number of subjects with diary cards completed and returned. Vaccination of older children, adolescents and adults against pertussis is now being proposed by some authorities to manage the recently observed epidemiological shift in the incidence of the disease to older age groups [8,26]. To achieve long-term protection, it is possible that subsequent doses of pertussis vaccine are required at regular intervals throughout life, irrespective of both past immunization history and exposure to the natural infection [27]. As is the case for most vaccine-preventable diseases, high vaccination coverage must be achieved before herd immunity can be acquired and control of infection is afforded the entire population [28]. Combination with an already routinely used booster vaccine such as the diphtheria-tetanus vaccine (Td) is generally accepted as not only the most efficient, but also the most cost-effective means of achieving high coverage [29,30]. However, it is important to ensure that neither the immunogenicity nor the reactogenicity profile of the combined vaccine is compromised. The assessment of immune response assumes greater significance in the case of dtpa vaccine, in which the diphtheria toxoid and pertussis antigen contents have been reduced to improve greater tolerability [31]. Earlier studies [26,32 38] have demonstrated safety, good tolerability, and immunogenicity of DTPa vaccines as compared with DTPw vaccines when administered as booster doses in infants, preschool children and adults. However, the reactogenicity of DTPa vaccines is higher when used as a booster dose as compared with primary immunization [37,39]. This can be circumvented by using a reduced-antigen-content dtpa vaccine. Historical data have shown that reduced-antigen-content dtpa vaccines elicit immunogenicity profiles comparable with DTPa vaccines when administered as a booster dose [40]. Findings from other historical data indicate that vigorous booster responses can be elicited by reduced quantities of vaccine antigens in previously primed subjects [41]. The reduction of diphtheria toxoid and pertussis antigen contents did not have a deleterious effect on the immunogenicity of the vaccine when administered as a booster dose. The results of these dtpa vaccine studies are consistent with these earlier results as demonstrated by seroprotection/ vaccine response to all antibodies in a majority of the subjects and absence of Grade 3-solicited symptoms, unsolicited symptoms or serious adverse events. In conclusion, these studies suggest that the reducedantigen-content dtpa vaccine may be safely and effectively administered as a booster dose to children aged six to eight years and adolescents/young adults aged 15 to 20 years who were previously primed with DTP vaccine. The dtpa combination vaccine offers the benefits of lower reactogenicity as compared with the DTPa vaccines, satisfactory immunogenicity profile, and increased compliance. Given the recent epidemiological data showing an increase in the susceptibility of older age groups to pertussis and the apparent lack of protection against diphtheria, there is a need for harmonized, universal primary vaccination followed by a booster policy [31]. A reduced-antigencontent dtpa vaccine, with its improved tolerability and the
5 L.-M. Huang et al. / Journal of Adolescent Health 37 (2005) 517.e1 517.e5 517.e5 ability to boost titres against all three diseases, meets the growing need for a booster vaccine by offering protection against pertussis infection and providing the opportunity for control of the disease in these age groups. Acknowledgment This study was funded by a grant from GlaxoSmithKline Biologicals, Rixensart, Belgium. References [1] Davey S. The vaccine challenge. In: State of the World s Vaccines and Immunisation. Geneva: World Health Organization and United Nations Children s Fund, 1996:1 25. [2] Giammanco A, Chiarini A, Stroffolini T, et al. Seroepidemiology of pertussis in Italy. Rev Infect Dis 1991;13: [3] Black S. Epidemiology of pertussis. Pediatr Infect Dis J 1997; 16(suppl): [4] Baron S, Njamkepo E, Grimprel E, et al. Epidemiology of pertussis in French hospitals in 1993 and 1994: thirty years after a routine use of vaccination. Pediatr Infect Dis J 1998;17: [5] Centers for Disease Control and Prevention. Pertussis outbreaks Massachusetts and Maryland, MMWR 1993;147: [6] Cromer BA, Goydos J, Hackell J, et al. Unrecognized pertussis infection in adolescents. Am J Dis Child 1993;147: [7] He Q, Viljanen MK, Nikkari S, et al. Outcomes of Bordetella pertussis infection in different age groups of an immunised population. J Infect Dis 1994;17: [8] Keitel WA, Edwards KM. Pertussis in adolescents and adults: time to reimmunize? Semin Respir Infect 1995;10:51 7. [9] Nennig ME, Shinefield HR, Edwards KM, et al. Prevalence and incidence of adult pertussis in an urban population. JAMA 1996;275: [10] Robertson PW, Goldberg H, Jarvie BH, et al. Bordetella pertussis infection: a cause of persistent cough in adults. Med J Aust 1987;147: [11] Bass JW, Wittler RR. Return of epidemic pertussis in the United States. Pediatr Infect Dis J 1994;13: [12] Cherry JD, Baraff LJ, Hewlett E. The past, present and future of pertussis. The role of adults in epidemiology and future control. West J Med 1989;150: [13] Hoppe JE. Update on epidemiology, diagnosis, and treatment of pertussis. Eur J Clin Microbiol Infect Dis 1996;15: [14] Mortimer EA Jr. Pertussis and its prevention: a family affair. J Infect Dis 1990;161: [15] Nelson JD. The changing epidemiology of pertussis in young infants: the role of adults as reservoirs of infection. Am J Dis Child 1978; 132: [16] Mertsola J, Ruuskanen O, Eerola E, Viljanen MK. Intrafamilial spread of pertussis. J Pediatr 1983;103: [17] Long SS, Welkon CJ, Clark JL. Widespread silent transmission of pertussis in families: antibody correlates of infection and symptomatology. J Infect Dis 1990;161: [18] Izurieta HS, Kenyon TA, Strebel PM, et al. Risk factors for pertussis in young infants during an outbreak in Chicago in Clin Infect Dis 1996;22: [19] Fine PE. Adult pertussis: a salesman s dream and an epidemiologist s nightmare. Biologicals 1997;25: [20] Deville JG, Cherry JD, Christenson PD, et al. Frequency of unrecognized Bordetella pertussis infections in adults. Clin Infect Dis 1995;21: [21] National Advisory Committee on Immunisation, the Advisory Committee on Epidemiology, the Canadian Paediatric Society. Statement on management of persons exposed to pertussis and pertussis outbreak control. Can Med Assoc J 1995;152: [22] Immunization Practices Advisory Committee. Diphtheria, tetanus and pertussis: recommendations for vaccine use and other preventive measures. MMWR Recomm Rep 1991;40:1 28. [23] Decker MD, Edwards KM, Steinhoff MC, et al. Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics 1995;96: [24] Pichichero ME. Acellular pertussis vaccines. Towards an improved safety profile. Drug Saf 1996;15: [25] Kimura M, Kuno-Sakai H, Sato Y, et al. A comparative trial of the reactogenicity and immunogenicity of Takeda acellular pertussis vaccine combined with tetanus and diphtheria toxoids. Outcome in 3- to 8-month-old infants, 9- to 23-month-old infants and children, and 24- to 30-month-old children. Am J Dis Child 1991;145: [26] Edwards KM, Decker MD, Graham BS, et al. Adult immunization with acellular pertussis vaccine. JAMA 1993;269:53 6. [27] Liese JG, Stojanov S, Belohradsky BH. Pertussis vaccination with acellular vaccines. Tolerance effectiveness current vaccination recommendations. Fortschr Med 1997;115:22 7. [28] Anderson RM, May RM. Immunization and herd immunity. Lancet 1990;335: [29] Hadler SC. Cost benefit of combining antigens. Biologicals 1994;22: [30] Begue P, Grimprel E. Future combined vaccines. J Infect Dis 1996; 174(suppl 3):S [31] Van der Wielen M, Van Damme P, Joossens E, et al. A randomized controlled trial with a diphtheria-tetanus-acellular pertussis (dtpa) vaccine in adults. Vaccine 2000;18(20): [32] Ruuskanen O, Noel A, Putto-Laurila A, et al. Development of an acellular pertussis vaccine and its administration as a booster in healthy adults. Vaccine 1991;9: [33] Annunziato PW, Rothstein EP, Bernstein HH, et al. Comparison of a three-component acellular pertussis vaccine with a whole-cell pertussis vaccine in 4- through 6-year-old children. Arch Pediatr Adolescent Med 1994;148(5): [34] Bernstein HH, Rothstein EP, Reisinger KS, et al. Comparison of a three-component acellular pertussis vaccine with a whole-cell pertussis vaccine in 15- through 20-month-old infants. Pediatrics 1994;93: [35] Kanra G, Ceyhan M, Vandevoorde D, Bogaerts H. Acellular pertussis diphtheria-tetanus-pertussis vaccine containing separately purified pertussis toxoid, filamentous hemagglutinin and 69 kda outer membrane protein as a booster in children. Eur J Pediatr 1993;152: [36] Englund JA, Decker MD, Edwards KM, et al. Acellular and wholecell pertussis vaccines as a booster dose: a multicentre study. Pediatrics 1994;93: [37] Pichichero ME, Deloria MA, Rennels MB, et al. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20- month-old children. Pediatrics 1997;100: [38] Schmitt H-J, Beutel K, Schuind A, et al. Reactogenicity and immunogenicity of a booster dose of a combined diphtheria, tetanus, and tricomponent acellular pertussis vaccine at fourteen to twenty-eight months of age. J Pediatr 1997;130: [39] Zepp F. Reactogenicity of booster doses: field experiences in Germany. Proceedings of the Acellular Pertussis Vaccine Conference. Bethesda, MD: [40] Dagan R, Igbaria K, Piglansky L, et al. Reactogenicity and immunogenicity of reduced antigen content diphtheria-tetanus-acellular pertussis vaccines as a booster in 4 7-year-old children primed with diphtheria-tetanus-whole cell pertussis vaccine before 2 years of age. Vaccine 1999;17(20 21): [41] Minh NNT, He Q, Ramalho A, et al. Acellular vaccines containing reduced quantities of pertussis antigens as a booster in adolescents. Pediatrics 1999;104(6):
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationTo demonstrate that DTPa-HBV-IPV/Hib-MenC-TT co-administered with 10Pn, is non-inferior to DTPa-HBV-IPV/Hib coadministered
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy Number: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationJ Formos Med Assoc 2011;110(6): Contents lists available at ScienceDirect. Journal of the Formosan Medical Association
Volume 110 Number 6 June 2011 Perinatal factors and psychiatric disorders Intracellular defense against HIV Hypolipidemia and anti-hcv therapy Drug resistance of tuberculosis in diabetes patients Formosan
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationCLINICAL PHARMACOLOGY INFANRIX DTPa vaccine, induces antibodies against all vaccine components.
INFANRIX PRODUCT INFORMATION NAME OF THE MEDICINE Diphtheria-tetanus-acellular pertussis (DTPa) vaccine DESCRIPTION INFANRIX DTPa vaccine is a sterile suspension which contains diphtheria toxoid, tetanus
More informationBOOSTRIX PRODUCT INFORMATION
BOOSTRIX PRODUCT INFORMATION NAME OF THE MEDICINE Combined diphtheria-tetanus-acellular pertussis (dtpa) vaccine DESCRIPTION BOOSTRIX dtpa vaccine is a sterile suspension which contains diphtheria toxoid,
More informationBOOSTRIX. Combined diphtheria, tetanus, acellular pertussis vaccine
BOOSTRIX Combined diphtheria, tetanus, acellular pertussis vaccine QUALITATIVE AND QUANTITATIVE COMPOSITION 1 dose (0.5 ml) contains: Diphtheria toxoid 1 Tetanus toxoid 1 Bordetella pertussis antigens
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSurvey of pertussis in patients with prolonged cough
Pertussis J Microbiol in patients Immunol with Infect prolonged cough 2006;39:54-58 Original Article Survey of pertussis in patients with prolonged cough Jen-Jan Hu 1, Chun-Yi Lu 2, Luan-Yin Chang 2, Chin-Hao
More informationBOOSTRIX -IPV. BOOSTRIX-IPV is a combined diphtheria, tetanus, acellular pertussis (dtpa) and inactivated poliovirus vaccine.
BOOSTRIX-IPV Product Information 1(16) BOOSTRIX -IPV NAME OF THE DRUG BOOSTRIX-IPV is a combined diphtheria, tetanus, acellular pertussis (dtpa) and inactivated poliovirus vaccine. DESCRIPTION BOOSTRIX-IPV
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Study vaccines Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More information1. QUALITATIVE AND QUANTITATIVE COMPOSITION
INFANRIX 1. QUALITATIVE AND QUANTITATIVE COMPOSITION contains diphtheria toxoid, tetanus toxoid, and three purified pertussis antigens [pertussis toxoid (PT), filamentous haemagglutinin (FHA) and 69 kilodalton
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationBOOSTRIX -IPV PRODUCT INFORMATION. BOOSTRIX-IPV is a combined diphtheria, tetanus, acellular pertussis (dtpa) and inactivated poliovirus vaccine.
BOOSTRIX -IPV PRODUCT INFORMATION NAME OF THE MEDICINE BOOSTRIX-IPV is a combined diphtheria, tetanus, acellular pertussis (dtpa) and inactivated poliovirus vaccine. DESCRIPTION BOOSTRIX-IPV is a sterile
More informationSynopsis of study HBV-314 BST 280 (108988)
Synopsis of study HBV-314 BST 280 (108988) Pharmaceutical entrepreneur: GlaxoSmithKline GmbH & Co. KG Prinzregentenplatz 9 81675 Munich Germany Personal identifiable data of investigators (name / full
More informationUpdated WHO position paper on pertussis vaccines. Geneva, Switzerland October 2010
Updated WHO position paper on pertussis vaccines Geneva, Switzerland October 2010 Introduction Replaces the position paper on pertussis vaccines published in the Weekly Epidemiological Record in January
More informationINFANRIX-IPV Product Information 1(13) INFANRIX IPV
INFANRIX-IPV Product Information 1(13) INFANRIX IPV NAME OF THE DRUG INFANRIX IPV vaccine is a combined diphtheria, tetanus, acellular pertussis (DTPa) and inactivated poliovirus vaccine. DESCRIPTION INFANRIX
More informationBOOSTRIX QUALITATIVE AND QUANTITATIVE COMPOSITION PHARMACEUTICAL FORM CLINICAL PARTICULARS. Indications. Dosage and Administration
BOOSTRIX Diphtheria, tetanus and pertussis (acellular, component) vaccine (adsorbed, reduced antigen(s) content) QUALITATIVE AND QUANTITATIVE COMPOSITION 1 dose (0.5 ml) contains: Diphtheria toxoid 1 Tetanus
More informationFor the additional vaccination phase
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationLong-term follow-up at Month 198: 21 October 2008 to 07 December Long-term follow-up at Month 186: 01 October 2007 to 19 December 2008
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationBoostrix polio. 3. PHARMACEUTICAL FORM Suspension for injection. 4. CLINICAL PARTICULARS
Boostrix polio 1. NAME OF THE MEDICINAL PRODUCT boostrix polio Combined diphtheria, tetanus, acellular pertussis and enhanced inactivated polio vaccine. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION boostrix
More informationsubjects having anti-hav antibody concentrations 100 miu/ml at the pre- additional vaccination time point.
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationINFANRIX IPV PRODUCT INFORMATION
INFANRIX IPV PRODUCT INFORMATION NAME OF THE MEDICINE INFANRIX IPV vaccine is a combined diphtheria, tetanus, acellular pertussis (DTPa) and inactivated poliovirus vaccine. DESCRIPTION INFANRIX IPV vaccine
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationPublic Assessment Report for paediatric studies submitted in accordance with Article 45 of Regulation (EC) No1901/2006, as amended.
Public Assessment Report for paediatric studies submitted in accordance with Article 45 of Regulation (EC) No1901/2006, as amended (Purified Diphtheria Toxoid Purified Tetanus Toxoid Adsorbed purified
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationInfanrix TM Diphtheria (D), tetanus (T), pertussis (acellular, component) (Pa) vaccine
Infanrix TM Diphtheria (D), tetanus (T), pertussis (acellular, component) (Pa) vaccine QUALITATIVE AND QUANTITATIVE COMPOSITION Infanrix TM contains diphtheria toxoid, tetanus toxoid and three purified
More informationHelen Marshall a, *, Peter McIntyre b, Don Roberton a, Leonie Dinan a, Karin Hardt c
International Journal of Infectious Diseases (2010) 14, e41 e49 http://intl.elsevierhealth.com/journals/ijid Primary and booster immunization with a diphtheria, tetanus, acellular pertussis, hepatitis
More informationStudy No.: Title: Rationale: Phase: Study Periods: Study Design: Centers: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationPertussis is a significant cause of mortality in early infancy
ORIGINAL STUDIES Acellular Pertussis Vaccine at Birth and One Month Induces Antibody Responses By Two Months of Age Nicholas Wood, MB BS, FRACP,* Peter McIntyre, MB BS, FRACP, FAFPHM, PhD,* Helen Marshall,
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSee 17 for PATIENT COUNSELING INFORMATION. Revised: 10/2016
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use BOOSTRIX safely and effectively. See full prescribing information for BOOSTRIX. BOOSTRIX (Tetanus
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationBoostrix version 1. Elements for a Public Summary. Overview of disease epidemiology. Pertussis Epidemiology
Boostrix 2.1.2015 version 1 VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Pertussis Epidemiology Pertussis (whooping cough), which is caused by Bordetella pertussis bacteria,
More informationPertussis Control in New Zealand How can we do better?
Pertussis Control in New Zealand How can we do better? 1 Conflict of interest In the past I have received support for vaccine work, clinical trials, presentation of papers and conference attendance from
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Center: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Note: Phase: Study Period: Study Design: Centres: Indication: Treatment: Hib-MenCY F1 Group Hib-MenCY F2 Group
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationElements for a Public Summary
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Pertussis Epidemiology Pertussis (whooping cough), which is caused by Bordetella pertussis bacteria, is an easily spread respiratory
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationMenC. MenW MenY
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationDuring the past 2 decades, several acellular
Safety and Immunogenicity of Six Acellular Pertussis Vaccines and One Whole-Cell Pertussis Vaccine Given as a Fifth Dose in Four- to Six-Year-Old Children Michael E. Pichichero, MD*; Kathryn M. Edwards,
More informationNo :
No.40 / - http://www.who.int/wer :( )..... ( ). / http://www.who.int/immunization/documents/positionpapers/en/index.html. :. ( ). ( ) ). (.... 1 .. (
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationDuring the past decade, additions to the recommended childhood immunization
Immunogenicity and Safety of a Combination Diphtheria, Tetanus Toxoid, Acellular Pertussis, Hepatitis B, and Inactivated Poliovirus Vaccine Coadministered with a 7-Valent Pneumococcal Conjugate Vaccine
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationGlobal strategies for immunization against
Paediatrica Indonesiana VOLUME 53 November NUMBER 6 Original Article Safety and immunogenicity of the DTP/HB /Hib combination vaccine: phase I study Kusnandi Rusmil, 1 Eddy Fadlyana, 1 Novilia Sjafri Bachtiar,
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationBOOSTRIX POLIO. 3. PHARMACEUTICAL FORM Suspension for injection.
BOOSTRIX POLIO 1. NAME OF THE MEDICINAL PRODUCT boostrix polio Diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine (adsorbed, reduced antigen(s) content) 2. QUALITATIVE
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationFor the use only of Registered Medical Practitioners or a Hospital or a Laboratory
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory INFANRIX Diphtheria Tetanus and Pertussis (Acellular Component) Vaccine (Adsorbed) Ph. Eur. 1. NAME OF THE MEDICINAL PRODUCT
More informationWith the increasing number of recommended. Clinical Evaluation of a DTaP-HepB-IPV Combined Vaccine REPORTS
Clinical Evaluation of a DTaP-HepB-IPV Combined Vaccine Susan Partridge, BSN, MBA; and Sylvia H. Yeh, MD Abstract Objective: To provide an overview of prelicensure clinical data for a new pediatric vaccine
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Pre-filled syringe: IPV-Boostrix suspension for injection in pre-filled syringe Diphtheria, tetanus, pertussis (acellular, component)
More informationVaccination with 10-valent pneumococcal conjugate vaccine in infants according to HIV
Supplemental Digital Content 1. Methodology Inclusion and exclusion criteria Eligible participants were infants between and including 6 10 weeks of age at the time of the first vaccination, who were free
More informationSee 17 for PATIENT COUNSELING INFORMATION. Revised: 03/2011
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use BOOSTRIX safely and effectively. See full prescribing information for BOOSTRIX. BOOSTRIX (Tetanus
More informationHBV-2 Group: neonates born to HBsAg+ and HBeAg+ mothers who received a 4-dose vaccination regimen (Part of
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Center: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationInfanrix IPV. Copyright , MIMS Australia Page 1 of 6
Infanrix IPV MIMS Abbreviated Prescribing Information Diphtheria toxoid; pertussis vaccine; poliomyelitis vaccine; tetanus toxoid GlaxoSmithKline Australia Section: 10(a) Vaccines - Immunology Use in pregnancy:
More informationResearch. Pertussis (whooping cough) is a respiratory
Research OBSTETRICS Maternal immunization with tetanus diphtheria pertussis vaccine: effect on maternal and neonatal serum antibody levels Stanley A. Gall, MD; John Myers, PhD; Michael Pichichero, MD OBJECTIVE:
More informationRecent studies, including clinical trials, have
Reactogenicity and Immunogenicity at Preschool Age of a Booster Dose of Two Three-Component Diphtheria-Tetanus-Acellular Pertussis Vaccines in Children Primed in Infancy With Acellular Vaccines Alberto
More informationAnalysis of safety The analysis was performed on the Total Vaccinated cohort.
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationDevelopment of Recombinant Pertussis Vaccines
Development of Recombinant Pertussis Vaccines Wassana Wijagkanalan, PhD BioNet-Asia Co., Ltd, Bangkok, Thailand DCVMN Workshop: Global Registration and Vaccine Shortage 6-10 March 2017, Taipei, Taiwan
More informationINFANRIX hexa. Combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine
INFANRIX hexa Product Information 1(12) INFANRIX hexa Combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine DESCRIPTION INFANRIX hexa
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationThese results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. Name of Sponsor/ Company: Sanofi Pasteur Study Code: Study Identifier:
More informationAnalysis of immunogenicity
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationPertussis Epidemiology and Vaccine Impact in the United States
Pertussis Epidemiology and Vaccine Impact in the United States Stacey Martin, MSc Epidemiology Team Lead Meningitis and Vaccine Preventable Diseases Branch Centers for Disease Control and Prevention Presented
More informationPreventing Tetanus, Diphtheria, and Pertussis Among Adolescents: Use of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccines
Morbidity and Mortality Weekly Report Recommendations and Reports March 24, 2006 / Vol. 55 / No. RR-3 Preventing Tetanus, Diphtheria, and Pertussis Among Adolescents: Use of Tetanus Toxoid, Reduced Diphtheria
More informationAUSTRALIAN PRODUCT INFORMATION
AUSTRALIAN PRODUCT INFORMATION NAME OF THE MEDICINE ADACEL Pertussis Vaccine-Acellular Combined with Diphtheria and Tetanus Toxoids (Adsorbed) DESCRIPTION ADACEL is a sterile, uniform, cloudy, white suspension
More informationPertussis: Clinical Review and Colorado s Epidemic
Pertussis: Clinical Review and Colorado s Epidemic Today s Speakers: Robert Brayden, MD, Professor of Pediatrics, University of Colorado School of Medicine, Children s Hospital Colorado Lisa Miller, MD,
More informationImmunisation Subcommittee of PTAC Meeting held 28 October 2015
Immunisation Subcommittee of PTAC Meeting held 28 October 2015 (minutes for web publishing) Immunisation Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationAcombination vaccine including diphtheria,
Immunogenicity and Safety of Combined Diphtheria-Tetanus-Whole cell Pertussis- Hepatitis B/ Haemophilus Influenzae Type b Vaccine in Indian Infants S.B. Bavdekar*, P.P. Maiya*, S.D. Subba Rao, S.K. Datta**
More informationINFANRIX -penta Datasheet
INFANRIX -penta Datasheet NAME OF THE MEDICINE INFANRIX -penta Combined diphtheria, tetanus, acellular pertussis, hepatitis B and inactivated polio vaccine. QUALITATIVE AND QUANTITATIVE COMPOSITION INFANRIX
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
he study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationPertussis: Trends, Prevention and Challenges Flor M. Munoz, MD Associate Professor Pediatric Infectious Diseases
Pertussis: Trends, Prevention and Challenges Flor M. Munoz, MD Associate Professor Pediatric Infectious Diseases Disclosure I do not have any relevant conflicts of interest to disclose. Page 1 xxx00.#####.ppt
More informationEDUCATIONAL COMMENTARY PERTUSSIS
EDUCATIONAL COMMENTARY PERTUSSIS Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE credits click on Earn CE Credits
More informationCellular Immunity in Adolescents and Adults following Acellular Pertussis Vaccine Administration
CLINICAL AND VACCINE IMMUNOLOGY, Mar. 2007, p. 288 292 Vol. 14, No. 3 1556-6811/07/$08.00 0 doi:10.1128/cvi.00364-06 Copyright 2007, American Society for Microbiology. All Rights Reserved. Cellular Immunity
More informationComparison of Five Commercial Enzyme-Linked Immunosorbent Assays for Detection of Antibodies to Bordetella pertussis
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, May 2000, p. 422 426 Vol. 7, No. 3 1071-412X/00/$04.00 0 Copyright 2000, American Society for Microbiology. All Rights Reserved. Comparison of Five Commercial
More informationImmunogenicity, Safety, and Antibody Persistence at 3, 5 and 10 Years Postvaccination in
CVI Accepts, published online ahead of print on 24 December 2014 Clin. Vaccine Immunol. doi:10.1128/cvi.00682-14 Copyright 2014, American Society for Microbiology. All Rights Reserved. 1 2 3 4 5 6 7 8
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationINFANRIX hexa. Combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine
INFANRIX hexa Combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine NAME OF THE MEDICINE INFANRIX hexa Combined Diphtheria-Tetanus-acellular
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationPertussis is an acute disease of the respiratory tract
Clinical Manifestations of Bordetella pertussis Infection in Immunized Children and Young Adults* Einat Yaari, MD; Yael Yafe-Zimerman, MD; Shepard B. Schwartz, MD; Paul E. Slater, MD, MPH; Pesach Shvartzman,
More informationPertussis. (Whole-cell pertussis vaccines) must not be frozen, but stored at 2 8 C. All wp vaccines have an expiry date of months.
Program Management 61_5 The wp vaccines have a considerably lower price than ap vaccines and, where resources are limited and the vaccine is well accepted by the local population, wp vaccine remains the
More informationKEY WORDS: Pertussis, Transplantation, Vaccination
Pertussis Immunity and Response to Tetanus-Reduced Diphtheria-Reduced Pertussis Vaccine (Tdap) after Autologous Peripheral Blood Stem Cell Transplantation Trudy N. Small, 1 Andrew D. Zelenetz, 2 Ariela
More information2013 About Pertussis (Whooping Cough)
2013 About Pertussis (Whooping Cough) Pertussis Pertussis, also known as whooping cough, is a highly contagious and often serious disease, especially in young children. 1,2 In adolescents and adults it
More informationD-QIV_LP 6-35m Group: Subjects aged 6-35 months received 1 or 2 doses of D-QIV_IP vaccine depending on vaccine-priming
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationjournal of medicine The new england Efficacy of an Acellular Pertussis Vaccine among Adolescents and Adults abstract
The new england journal of medicine established in 1812 october 13, 2005 vol. 353 no. 15 Efficacy of an Acellular Pertussis Vaccine among Adolescents and Adults Joel I. Ward, M.D., James D. Cherry, M.D.,
More informationJournal Club 3/4/2011
Journal Club 3/4/2011 Maternal HIV Infection and Antibody Responses Against Vaccine-Preventable Diseases in Uninfected Infants JAMA. 2011 Feb 9;305(6):576-84. Jones et al Dept of Pediatrics, Imperial College,
More informationSafety and Immunogenicity of Heptavalent Pneumococcal Conjugate Vaccine Booster in Taiwanese Toddlers
ORIGINAL ARTICLE Safety and Immunogenicity of Heptavalent Pneumococcal Conjugate Vaccine Booster in Taiwanese Toddlers Pei-Lan Shao, Chun-Yi Lu, 1 Luan-Yin Chang, 1 Fu-Yuan Huang, 2 Chin-Yun Lee, 1 Po-Ren
More informationINFANRIX hexa. Combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine
INFANRIX hexa Combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine NAME OF THE MEDICINE INFANRIX hexa Combined Diphtheria-Tetanus-acellular
More informationDiphtheria, Tetanus, and Pertussis. DTaP/DT and Tdap/Td Vaccines
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Diphtheria, Tetanus, and Pertussis DTaP/DT and Tdap/Td Vaccines Jean C. Smith, MD, MPH Medical Officer
More information